These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1292 related articles for article (PubMed ID: 18820719)
21. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695 [TBL] [Abstract][Full Text] [Related]
22. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. McColl DJ; Chen X Antiviral Res; 2010 Jan; 85(1):101-18. PubMed ID: 19925830 [TBL] [Abstract][Full Text] [Related]
23. HIV integrase as a target for antiretroviral therapy. Hazuda DJ Curr Opin HIV AIDS; 2012 Sep; 7(5):383-9. PubMed ID: 22871634 [TBL] [Abstract][Full Text] [Related]
24. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity. Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234 [TBL] [Abstract][Full Text] [Related]
25. Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site. Wielens J; Headey SJ; Jeevarajah D; Rhodes DI; Deadman J; Chalmers DK; Scanlon MJ; Parker MW FEBS Lett; 2010 Apr; 584(8):1455-62. PubMed ID: 20227411 [TBL] [Abstract][Full Text] [Related]
26. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Robinson WE; Cordeiro M; Abdel-Malek S; Jia Q; Chow SA; Reinecke MG; Mitchell WM Mol Pharmacol; 1996 Oct; 50(4):846-55. PubMed ID: 8863829 [TBL] [Abstract][Full Text] [Related]
27. New targets for inhibitors of HIV-1 replication. Moore JP; Stevenson M Nat Rev Mol Cell Biol; 2000 Oct; 1(1):40-9. PubMed ID: 11413488 [TBL] [Abstract][Full Text] [Related]
28. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Lataillade M; Chiarella J; Kozal MJ Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566 [TBL] [Abstract][Full Text] [Related]
29. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. Mekouar K; Mouscadet JF; Desmaële D; Subra F; Leh H; Savouré D; Auclair C; d'Angelo J J Med Chem; 1998 Jul; 41(15):2846-57. PubMed ID: 9667973 [TBL] [Abstract][Full Text] [Related]
30. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors. Plewe MB; Butler SL; Dress KR; Hu Q; Johnson TW; Kuehler JE; Kuki A; Lam H; Liu W; Nowlin D; Peng Q; Rahavendran SV; Tanis SP; Tran KT; Wang H; Yang A; Zhang J J Med Chem; 2009 Nov; 52(22):7211-9. PubMed ID: 19873974 [TBL] [Abstract][Full Text] [Related]
31. Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration. Grobler JA; Stillmock KA; Hazuda DJ Methods; 2009 Apr; 47(4):249-53. PubMed ID: 19285556 [TBL] [Abstract][Full Text] [Related]
32. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922 [TBL] [Abstract][Full Text] [Related]
33. Development of integrase inhibitors for treatment of AIDS: an overview. Dubey S; Satyanarayana YD; Lavania H Eur J Med Chem; 2007 Sep; 42(9):1159-68. PubMed ID: 17367896 [TBL] [Abstract][Full Text] [Related]
34. Plant substances as anti-HIV agents selected according to their putative mechanism of action. Cos P; Maes L; Vanden Berghe D; Hermans N; Pieters L; Vlietinck A J Nat Prod; 2004 Feb; 67(2):284-93. PubMed ID: 14987070 [TBL] [Abstract][Full Text] [Related]
35. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059 [TBL] [Abstract][Full Text] [Related]
36. Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. Gardelli C; Nizi E; Muraglia E; Crescenzi B; Ferrara M; Orvieto F; Pace P; Pescatore G; Poma M; Ferreira Mdel R; Scarpelli R; Homnick CF; Ikemoto N; Alfieri A; Verdirame M; Bonelli F; Paz OG; Taliani M; Monteagudo E; Pesci S; Laufer R; Felock P; Stillmock KA; Hazuda D; Rowley M; Summa V J Med Chem; 2007 Oct; 50(20):4953-75. PubMed ID: 17824681 [TBL] [Abstract][Full Text] [Related]
37. No residual activity of raltegravir after development of 148 complex mutations in vivo. Khanlou H; Sayana S; Acosta E J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138 [No Abstract] [Full Text] [Related]
38. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond. Murphy RL AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882 [TBL] [Abstract][Full Text] [Related]
39. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Hazuda DJ; Anthony NJ; Gomez RP; Jolly SM; Wai JS; Zhuang L; Fisher TE; Embrey M; Guare JP; Egbertson MS; Vacca JP; Huff JR; Felock PJ; Witmer MV; Stillmock KA; Danovich R; Grobler J; Miller MD; Espeseth AS; Jin L; Chen IW; Lin JH; Kassahun K; Ellis JD; Wong BK; Xu W; Pearson PG; Schleif WA; Cortese R; Emini E; Summa V; Holloway MK; Young SD Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11233-8. PubMed ID: 15277684 [TBL] [Abstract][Full Text] [Related]